DelveInsight has launched a new report on “Primary Sclerosing Cholangitis (PSC) – Market Insights, Epidemiology, and Market Forecast-2030”.
DelveInsight’s “Primary Sclerosing Cholangitis (PSC) – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Primary Sclerosing Cholangitis (PSC), historical and forecasted epidemiology as well as the Primary Sclerosing Cholangitis (PSC) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some of the key facts of the Report:
-
The exact incidence and prevalence of the disorder is unknown. One estimate places the incidence at approximately 1 person per 100,000 in the general population in the United States or Europe.
-
According to the study
-
The prevalence of PSC in ulcerative colitis (UC) has been estimated to be ~5%.
-
Approximately 60%–70% of patients with PSC and UC are men, and age at diagnosis is usually 30–40 years. Among patients without UC, there is a slight female predominance.
Key benefits of the report:
1. Primary Sclerosing Cholangitis (PSC) market report covers a descriptive overview and comprehensive insight of the Primary Sclerosing Cholangitis (PSC) epidemiology and Primary Sclerosing Cholangitis (PSC) market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. The Primary Sclerosing Cholangitis (PSC) market report provides insights on the current and emerging therapies.
3. Primary Sclerosing Cholangitis (PSC) market report provides a global historical and forecasted market covering drug outreach in 7MM.
4. The Primary Sclerosing Cholangitis (PSC) market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Primary Sclerosing Cholangitis (PSC) market.
Request for sample pages: https://www.delveinsight.com/sample-request/primary-sclerosing-cholangitis-market
Primary Sclerosing Cholangitis (PSC): Overview
Primary sclerosing cholangitis (PSC) is a chronic, or long-term, disease that slowly damages the bile ducts. Bile is a digestive liquid that is made in the liver. It travels through the bile ducts to the gallbladder and the small intestine, where it helps digest fats and fatty vitamins.
The key players involved in the Primary Sclerosing Cholangitis (PSC) market:
-
Gilead Sciences
-
HighTide Therapeutics
-
Tobira Therapeutics
-
NGM Biopharmaceuticals
The launch of the emerging therapies is expected to significantly impact the Primary Sclerosing Cholangitis (PSC) treatment scenario in the upcoming years:-
Drug covered
-
GS-9674
-
HTD1801
-
Cenicriviroc
-
NGM282
Request a free sample report @https://www.delveinsight.com/sample-request/primary-sclerosing-cholangitis-market
Table of Contents
1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Primary Sclerosing Cholangitis (PSC) Patient Share (%) Overview at a Glance
5. Primary Sclerosing Cholangitis (PSC) Market Overview at a Glance
6. Primary Sclerosing Cholangitis (PSC) Disease Background and Overview
7. Primary Sclerosing Cholangitis (PSC) Epidemiology and Patient Population
8. Country-Specific Patient Population of Primary Sclerosing Cholangitis (PSC)
9. Primary Sclerosing Cholangitis (PSC) Current Treatment and Medical Practices
10. Unmet Needs
11. Primary Sclerosing Cholangitis (PSC) Emerging Therapies
12. Primary Sclerosing Cholangitis (PSC) Market Outlook
13. Country-Wise Primary Sclerosing Cholangitis (PSC) Market Analysis (2017–2030)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Primary Sclerosing Cholangitis (PSC) Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/